Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DNLI

DNLI - Denali Therapeutics Inc Stock Price, Fair Value and News

$20.59-0.11 (-0.53%)
Market Closed

62/100

DNLI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

DNLI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DNLI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DNLI Price Action

Last 7 days

4.6%

Last 30 days

4.6%

Last 90 days

14.5%

Trailing 12 Months

38.3%

DNLI RSI Chart

DNLI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DNLI Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-6.37

Price/Sales (Trailing)

10.13

Price/Free Cashflow

-7.74

DNLI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DNLI Fundamentals

DNLI Revenue

DNLI Earnings

Earnings (TTM)

-512.5M

Earnings Growth (Yr)

-12.02%

Earnings Growth (Qtr)

-1.3%

DNLI Profitability

Return on Equity

-50.56%

Return on Assets

-44.77%

Free Cashflow Yield

-12.93%

DNLI Investor Care

Shares Dilution (1Y)

9.21%

Diluted EPS (TTM)

-2.97

DNLI Alerts

  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024311.3M000
2023101.5M343.1M340.8M330.5M
202282.9M112.4M110.7M108.5M
2021263.9M192.2M120.4M48.7M
202026.1M27.7M23.5M335.7M
2019103.5M77.9M52.3M26.7M
2018000129.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Denali Therapeutics Inc

DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEdenalitherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES438

Denali Therapeutics Inc Frequently Asked Questions

DNLI is the stock ticker symbol of Denali Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Denali Therapeutics Inc is 3.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, DNLI's PE ratio (Price to Earnings) is -6.37 and Price to Sales (PS) ratio is 10.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNLI PE ratio will change depending on the future growth rate expectations of investors.